U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Multiple Myeloma Post-Transplant Lymphoproliferative Disorder

MedGen UID:
233860
•Concept ID:
C1335425
•
Neoplastic Process
Synonyms: Multiple Myeloma PTLD; Plasma Cell Myeloma Post-Transplant Lymphoproliferative Disorder; Plasma Cell Myeloma PTLD

Definition

A lymphoproliferative disorder that develops following an organ transplantation and exhibits multiple myeloma features. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMultiple Myeloma Post-Transplant Lymphoproliferative Disorder

Professional guidelines

PubMed

Daratumumab for the treatment of multiple myeloma.
Goldsmith SR, Foley N, Schroeder MA
Drugs Today (Barc) 2021 Oct;57(10):591-605. doi: 10.1358/dot.2021.57.10.3313853. PMID: 34713868
Frontline treatment for transplant-eligible multiple myeloma: A 6474 patients network meta-analysis.
Sekine L, Ziegelmann PK, Manica D, da Fonte Pithan C, Sosnoski M, Morais VD, Falcetta FS, Ribeiro MR, Salazar AP, Ribeiro RA
Hematol Oncol 2019 Feb;37(1):62-74. Epub 2018 Sep 20 doi: 10.1002/hon.2552. PMID: 30129104
New developments in post-transplant maintenance treatment of multiple myeloma.
Liu H, McCarthy P
Semin Oncol 2013 Oct;40(5):602-9. doi: 10.1053/j.seminoncol.2013.07.008. PMID: 24135405

Recent clinical studies

Etiology

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Zweegman S, Caillon H, Caillot D, Avet-Loiseau H, Delforge M, Dejoie T, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Schiano de Colella JM, van de Donk NW, Wuillème S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Hua W, Wang J, Tuozzo A, de Boer C, Rowe M, Vanquickelberghe V, Carson R, Vermeulen J, Corre J, Sonneveld P; Intergroupe Francophone du Myélome, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology and the CASSIOPEIA Investigators
Lancet Oncol 2024 Aug;25(8):1003-1014. Epub 2024 Jun 15 doi: 10.1016/S1470-2045(24)00282-1. PMID: 38889735
Autologous stem cell transplantation in multiple myeloma.
Ricciuti G, Falcone A, Cascavilla N, Martinelli G, Cerchione C
Panminerva Med 2020 Dec;62(4):220-224. Epub 2020 Sep 21 doi: 10.23736/S0031-0808.20.04114-2. PMID: 32955179
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P
Lancet 2019 Jul 6;394(10192):29-38. Epub 2019 Jun 3 doi: 10.1016/S0140-6736(19)31240-1. PMID: 31171419
Risk adapted post-transplant maintenance in multiple myeloma.
Vaxman I, Gertz M
Expert Rev Hematol 2019 Feb;12(2):107-118. doi: 10.1080/17474086.2019.1576521. PMID: 30696304
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group
Lancet 2019 Jan 19;393(10168):253-264. Epub 2018 Dec 10 doi: 10.1016/S0140-6736(18)33003-4. PMID: 30545780

Diagnosis

Daratumumab for the treatment of multiple myeloma.
Goldsmith SR, Foley N, Schroeder MA
Drugs Today (Barc) 2021 Oct;57(10):591-605. doi: 10.1358/dot.2021.57.10.3313853. PMID: 34713868
Autologous stem cell transplantation in multiple myeloma.
Ricciuti G, Falcone A, Cascavilla N, Martinelli G, Cerchione C
Panminerva Med 2020 Dec;62(4):220-224. Epub 2020 Sep 21 doi: 10.23736/S0031-0808.20.04114-2. PMID: 32955179
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P
Lancet 2019 Jul 6;394(10192):29-38. Epub 2019 Jun 3 doi: 10.1016/S0140-6736(19)31240-1. PMID: 31171419
Risk adapted post-transplant maintenance in multiple myeloma.
Vaxman I, Gertz M
Expert Rev Hematol 2019 Feb;12(2):107-118. doi: 10.1080/17474086.2019.1576521. PMID: 30696304
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group
Lancet 2019 Jan 19;393(10168):253-264. Epub 2018 Dec 10 doi: 10.1016/S0140-6736(18)33003-4. PMID: 30545780

Therapy

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Zweegman S, Caillon H, Caillot D, Avet-Loiseau H, Delforge M, Dejoie T, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Schiano de Colella JM, van de Donk NW, Wuillème S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Hua W, Wang J, Tuozzo A, de Boer C, Rowe M, Vanquickelberghe V, Carson R, Vermeulen J, Corre J, Sonneveld P; Intergroupe Francophone du Myélome, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology and the CASSIOPEIA Investigators
Lancet Oncol 2024 Aug;25(8):1003-1014. Epub 2024 Jun 15 doi: 10.1016/S1470-2045(24)00282-1. PMID: 38889735
Autologous stem cell transplantation in multiple myeloma.
Ricciuti G, Falcone A, Cascavilla N, Martinelli G, Cerchione C
Panminerva Med 2020 Dec;62(4):220-224. Epub 2020 Sep 21 doi: 10.23736/S0031-0808.20.04114-2. PMID: 32955179
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P
Lancet 2019 Jul 6;394(10192):29-38. Epub 2019 Jun 3 doi: 10.1016/S0140-6736(19)31240-1. PMID: 31171419
Risk adapted post-transplant maintenance in multiple myeloma.
Vaxman I, Gertz M
Expert Rev Hematol 2019 Feb;12(2):107-118. doi: 10.1080/17474086.2019.1576521. PMID: 30696304
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group
Lancet 2019 Jan 19;393(10168):253-264. Epub 2018 Dec 10 doi: 10.1016/S0140-6736(18)33003-4. PMID: 30545780

Prognosis

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Zweegman S, Caillon H, Caillot D, Avet-Loiseau H, Delforge M, Dejoie T, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Schiano de Colella JM, van de Donk NW, Wuillème S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Hua W, Wang J, Tuozzo A, de Boer C, Rowe M, Vanquickelberghe V, Carson R, Vermeulen J, Corre J, Sonneveld P; Intergroupe Francophone du Myélome, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology and the CASSIOPEIA Investigators
Lancet Oncol 2024 Aug;25(8):1003-1014. Epub 2024 Jun 15 doi: 10.1016/S1470-2045(24)00282-1. PMID: 38889735
Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma.
Romano A, Santoro M, Conticello C, Siragusa S, DI Raimondo F, Martinelli G, Cerchione C
Panminerva Med 2021 Mar;63(1):13-20. Epub 2020 Sep 21 doi: 10.23736/S0031-0808.20.04141-5. PMID: 32955184
Newly Diagnosed Myeloma in 2020.
Moreau P, Touzeau C, Vij R, Goldsmith SR, Rosko AE
Am Soc Clin Oncol Educ Book 2020 Mar;40:1-15. doi: 10.1200/EDBK_280221. PMID: 32315239
Hematologic malignancies of the gastrointestinal luminal tract.
Hanafy AK, Morani AC, Menias CO, Pickhardt PJ, Shaaban AM, Mujtaba B, Mellnick VM, Elsayes KM
Abdom Radiol (NY) 2020 Oct;45(10):3007-3027. doi: 10.1007/s00261-019-02278-8. PMID: 31707438
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.
Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P
Haematologica 2018 Feb;103(2):197-211. Epub 2017 Dec 7 doi: 10.3324/haematol.2017.174573. PMID: 29217780Free PMC Article

Clinical prediction guides

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Zweegman S, Caillon H, Caillot D, Avet-Loiseau H, Delforge M, Dejoie T, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Schiano de Colella JM, van de Donk NW, Wuillème S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Hua W, Wang J, Tuozzo A, de Boer C, Rowe M, Vanquickelberghe V, Carson R, Vermeulen J, Corre J, Sonneveld P; Intergroupe Francophone du Myélome, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology and the CASSIOPEIA Investigators
Lancet Oncol 2024 Aug;25(8):1003-1014. Epub 2024 Jun 15 doi: 10.1016/S1470-2045(24)00282-1. PMID: 38889735
Newly Diagnosed Myeloma in 2020.
Moreau P, Touzeau C, Vij R, Goldsmith SR, Rosko AE
Am Soc Clin Oncol Educ Book 2020 Mar;40:1-15. doi: 10.1200/EDBK_280221. PMID: 32315239
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P
Lancet 2019 Jul 6;394(10192):29-38. Epub 2019 Jun 3 doi: 10.1016/S0140-6736(19)31240-1. PMID: 31171419
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group
Lancet 2019 Jan 19;393(10168):253-264. Epub 2018 Dec 10 doi: 10.1016/S0140-6736(18)33003-4. PMID: 30545780
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.
Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P
Haematologica 2018 Feb;103(2):197-211. Epub 2017 Dec 7 doi: 10.3324/haematol.2017.174573. PMID: 29217780Free PMC Article

Recent systematic reviews

Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review.
Al-Ani F, Louzada M
Eur J Haematol 2017 Dec;99(6):479-488. Epub 2017 Oct 6 doi: 10.1111/ejh.12961. PMID: 28885719
In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review.
Oostvogels R, Uniken Venema SM, de Witte M, Raymakers R, Kuball J, Kröger N, Minnema MC
Bone Marrow Transplant 2017 Sep;52(9):1233-1240. Epub 2017 Jul 10 doi: 10.1038/bmt.2017.141. PMID: 28692028

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...